Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation

MeSH terms

• Female
• Fusion Proteins, bcr-abl* / genetics
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / pathology
• Male
• Middle Aged
• Mutation*
• Niacinamide / analogs & derivatives
• Protein Kinase Inhibitors / therapeutic use
• Pyrazoles / therapeutic use
• Remission Induction*